Trinity Street Asset Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-198,226
Closed -$44.9M 24
2020
Q3
$44.9M Sell
198,226
-48,649
-20% -$10.1M 5.46% 4
2020
Q2
$43M Buy
246,875
+7,902
+3% +$1.26M 6.37% 4
2020
Q1
$30.2M Buy
238,973
+46,104
+24% +$6.91M 5.17% 8
2019
Q4
$29.5M Buy
192,869
+7,094
+4% +$982K 4% 15
2019
Q3
$24.6M Buy
185,775
+41,400
+29% +$5.55M 3.82% 16
2019
Q2
$20.5M Buy
+144,375
New +$19.6M 3.98% 14

Other funds holding CRL

Trinity Street Asset Management's CRL Position: Q4 2020 in Review

Trinity Street Asset Management sold out of Charles River Laboratories (CRL) in Q4 2020, closing a stake of 198,226 shares — an estimated $44.9M sold.

Trinity Street Asset Management first reported a position in CRL in Q2 2019 and held it in 6 quarters. The position peaked at $44.9M in Q3 2020. 538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Trinity Street Asset Management reported no remaining Charles River Laboratories position as of Q4 2020 after selling out during the quarter.
  • Trinity Street Asset Management sold 198,226 Charles River Laboratories shares in Q4 2020, an estimated $44.9M.
  • Trinity Street Asset Management first reported a position in Charles River Laboratories in Q2 2019 and held it in 6 quarters.
  • Trinity Street Asset Management's Charles River Laboratories position peaked at $44.9M in Q3 2020.
  • 538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Trinity Street Asset Management's 13F filing for Q4 2020, filed 22 Jan 2021.